BioCentury
ARTICLE | Clinical News

ALXN1007: Phase I started

February 20, 2012 8:00 AM UTC

Alexion disclosed in its 4Q11 earnings that it began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate 0.06, 0.1, 0.3, 1, 3, 6 and 10 mg/kg IV ALXN1007 in about 56 healthy volunteers....